French pharma company Ipsen has agreed to buy cancer biotech Kartos Therapeutics of the US for $450 million upfront, gaining ...

Pressure is building on Amgen to withdraw rare disease therapy Tavneos, after the EMA's human medicine committee followed the FDA in recommending that its benefits no longer outweigh its risks. At its ...

At its latest R&D update, Moderna revealed a move into the pioneering in vivo CAR-T category, adding another treatment class ...

Designing and implementing global patient support programmes (PSPs) is becoming increasingly complex. While many programmes ...

As of 2026, women remain underrepresented in STEM fields, but initiatives like the Women and Underrepresented Minorities in ...

The industry tends to treat manufacturing as a back-end operational concern. For advanced therapies, it isn't. In cell and ...

Two years after its first approval for an ultra-rare lipid disorder, Ionis' Tryngolza has been approved by the FDA for severe ...

Around a third of adults in England are now living with obesity, and new cases are rising most quickly in younger adults, ...

CARSgen Therapeutics has claimed approval in China, its home market, for satricabtagene autoleucel (satri-cel), said to be ...

Details are starting to emerge of last week's cyberattack on Novo Nordisk, which now appears to have been a $25 million ...

The European Commission has opened an investigation into a marketing campaign run by Sanofi for an influenza vaccine, and whether it disparaged its only rival in the market. Specifically, it is ...

Hundreds of women with aggressive cervical cancer are to be offered MSD's Keytruda on the NHS in England, in the second ...